Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diovan Positioned For Growth Following Sales Force Shift, Novartis Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite disruption in first quarter, the company says a realignment of reps will help the hypertension drug by better targeting high-volume prescribing "tier one" doctors. Sales of the angiotensin II receptor blocker also will be aided by new dosage strengths, indications and price increases, Novartis says.
Advertisement

Related Content

Gleevec Sales Gains May Come From Increased Dosing Compliance
Gleevec Sales Gains May Come From Increased Dosing Compliance
Novartis Will Stand Tough On Sales Force Size, CEO Costa Says
Novartis Will Stand Tough On Sales Force Size, CEO Costa Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS062043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel